Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
16.45
-0.26 (-1.56%)
At close: Feb 10, 2026, 4:00 PM EST
16.53
+0.08 (0.49%)
After-hours: Feb 10, 2026, 4:29 PM EST
Nurix Therapeutics Revenue
In the fiscal year ending November 30, 2025, Nurix Therapeutics had annual revenue of $83.98M with 53.95% growth. Nurix Therapeutics had revenue of $13.58M in the quarter ending November 30, 2025, with 2.21% growth.
Revenue (ttm)
$83.98M
Revenue Growth
+53.95%
P/S Ratio
17.24
Revenue / Employee
$264,921
Employees
317
Market Cap
1.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2025 | 83.98M | 29.43M | 53.95% |
| Nov 30, 2024 | 54.55M | -22.44M | -29.15% |
| Nov 30, 2023 | 76.99M | 38.36M | 99.31% |
| Nov 30, 2022 | 38.63M | 8.88M | 29.84% |
| Nov 30, 2021 | 29.75M | 11.93M | 66.95% |
| Nov 30, 2020 | 17.82M | -13.30M | -42.73% |
| Nov 30, 2019 | 31.12M | -6.33M | -16.91% |
| Nov 30, 2018 | 37.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNRIX News
- 13 days ago - Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 25 days ago - Nurix Therapeutics: Why This Company Could Double In Value? - Seeking Alpha
- 4 weeks ago - Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside - Seeking Alpha
- 4 weeks ago - Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg Transcript - Seeking Alpha
- 2 months ago - Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - GlobeNewsWire